Zohydro is an opioid analgesic used in the management of severe, persistent pain that requires continuous, long-term symptomatic support. This application includes conditions presenting with significant symptomatic discomfort, such as those from long-term musculoskeletal disorders or specific neuropathic pain syndromes, where a high symptom load affects functional stability.

The medication's extended-release design provides sustained symptomatic control, offering a consistent level of analgesia over a prolonged period. This supports continuous, stable pain relief and may assist with maintaining a more stable experience of severe chronic symptoms, which contributes to easing the overall symptom load.

The medication is applied in clinical scenarios where supportive symptom management is appropriate, particularly when other treatment options are considered inadequate. The therapeutic scope for this medication is generally relevant to conditions that may benefit from chronic pain treatment and continuous therapy for severe symptomatic manifestations. Its single-entity formulation, containing only hydrocodone bitartrate, assists with establishing optimal symptomatic support and is applied across domains where additional symptomatic support is needed. This supports general well-being during symptomatic phases, assisting with maintaining functional stability.

---

Quick Fact: Relevant for Severe, Persistent Pain

Zohydro (hydrocodone bitartrate extended-release) is indicated for the management of severe pain that requires daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. It is not intended for use as an as-needed (prn) analgesic or for pain that is mild or moderate.

Limitations and Contraindications

Due to the significant risks associated with opioid use, Zohydro is reserved for patients for whom other non-opioid or immediate-release opioid options are ineffective or not tolerated. Patients must be carefully assessed for risk factors for addiction, abuse, and misuse prior to being prescribed this medication.

Zohydro should generally not be used (contraindicated) in individuals who have:

Condition	Reason for Contraindication
Significant Respiratory Depression	Risk of life-threatening breathing problems.
Acute/Severe Bronchial Asthma	Especially in unmonitored settings.
Known/Suspected Gastrointestinal Obstruction	Such as paralytic ileus.
Hypersensitivity	Allergy to hydrocodone or any component of the capsule.

Caution is also advised, with close monitoring required, for patients who are elderly or debilitated, have chronic pulmonary disease, head injury, increased intracranial pressure, or concomitant use of central nervous system (CNS) depressants, including alcohol.

Interactions with other medicines and products

Official regulatory information for Zohydro (Hydrocodone Bitartrate) defines interaction patterns based on pharmacokinetic and pharmacodynamic mechanisms documented in government drug labels. This section details the formally classified interactions and necessary administration constraints.

Pharmacokinetic and Contraindicated Drug Interactions

Interaction Type	Interacting Substance/Class	Official Interaction Statement
Pharmacokinetic	CYP3A4 Inhibitors (strong/moderate)	May result in increased hydrocodone plasma concentration.
Pharmacokinetic	CYP3A4 Inducers (strong/moderate)	May result in decreased hydrocodone plasma concentration or withdrawal symptoms.
Contraindicated	Monoamine Oxidase Inhibitors (MAOIs)	Concomitant use is forbidden; a minimum 14-day separation is required.

Pharmacodynamic and Substance Interactions

Interaction Type	Interacting Substance/Class	Official Interaction Statement
Pharmacodynamic	CNS Depressants (e.g., benzodiazepines, muscle relaxants)	Results in an additive depressant effect.
Pharmacodynamic	Serotonergic Drugs	May lead to serotonin syndrome due to additive serotonergic activity.
Drug-Substance	Alcohol	Co-ingestion is restricted due to the potential for rapid and excessive increase in plasma levels.

Co-administration of opioid mixed agonists/antagonists, such as pentazocine, is restricted as it may reduce analgesic efficacy. Furthermore, patients with severe hepatic impairment may experience a heightened risk of adverse effects due to reduced clearance, which is a population-specific interaction consideration noted in the product labeling.

Zohydro, containing hydrocodone bitartrate, functions as a full agonist at central nervous system mu (mu) opioid receptors (MOR), with secondary activity at delta (delta) opioid receptors (DOR). Both MOR and DOR are G-protein coupled receptors (GPCRs) that couple to the inhibitory Gi/Go class of G-proteins.

Binding of the hydrocodone agonist stabilizes the active receptor conformation, initiating G-protein activation. The alphai/o subunit dissociates and inhibits the enzyme adenylyl cyclase (AC), resulting in decreased intracellular concentration of cyclic adenosine monophosphate (cAMP). Simultaneously, the released Gbetagamma subunits act on ion channels. This action hyperpolarizes the neuron by activating inwardly rectifying potassium channels (GIRK), which increases potassium efflux. The Gbetagamma subunits also inhibit the opening of voltage-gated calcium channels (VGCCs) on the presynaptic terminal.

These intracellular changes lead to a reduction in neuronal excitability. Presynaptically, the inhibition of calcium influx decreases the release of excitatory neurotransmitters, such as substance P and glutamate. Postsynaptically, the hyperpolarization reduces the neuron's ability to fire an action potential. This combined action modulates neuronal transmission within the central and peripheral nervous systems, particularly along the descending inhibitory pathways and in the dorsal horn of the spinal cord, leading to system-level modulation of sensory signaling and depression of respiratory drive.

Zohydro ER (hydrocodone bitartrate extended-release capsules) is intended for oral administration only and is used on a fixed schedule. Due to its extended-release design, the medicine is not indicated as an as-needed (prn) analgesic. The standard dosing approach requires administration every 12 hours.

Administration Scope

Feature	Instruction
Route of administration	Oral.
Dosing schedule (Opioid-Naïve)	Initiate with 10 mg capsules every 12 hours.
Frequency pattern	Twice daily (every 12 hours), on a fixed schedule.
Timing in relation to meals	May be taken with or without food.

Procedural and Dosing Rules

The initiation of Zohydro is structured based on the patient's prior opioid experience. For individuals who are opioid-naïve, the starting dose is 10 mg every 12 hours. Dose adjustment, or titration, may occur every 3 to 7 days using increments of 10 mg every 12 hours. A single dose greater than 40 mg, or a total daily dose over 80 mg, is generally reserved for patients who have already established opioid tolerance.

For proper consumption, the capsules must be swallowed whole and are not to be cut, broken, chewed, crushed, or dissolved, as this would compromise the extended-release mechanism. Furthermore, the protocol for discontinuing the medicine is a gradual downward titration to prevent withdrawal, as the dose should not be stopped abruptly.

Population-specific adjustments define the lowest initial dose for certain groups: patients with severe hepatic impairment must be initiated with the lowest dose of 10 mg every 12 hours, and a low initial dose is also specified for patients with renal impairment.

Research Evidence / Overview of Studies for Zohydro (Hydrocodone Bitartrate Extended-Release)

---

Evidence for Use in Severe, Persistent Chronic Pain

Zohydro was studied for the management of severe chronic pain that requires continuous, around-the-clock opioid treatment. The core evidence for this medication came from formal clinical trials, specifically randomized, double-blind, placebo-controlled trials (RCTs). These trials were observed in patients with a pre-existing diagnosis of chronic pain. The research examined outcomes related to monitoring pain intensity, primarily focusing on how symptoms measured by daily pain intensity scores were monitored in the observed populations over time.

The key trials primarily centered on patients dealing with chronic low back pain (CLBP). Findings describe patterns observed in the studies over the short-term treatment period; researchers also monitored patterns observed in patients receiving a placebo. This research provides insight into short-term changes in patient-reported outcomes describing perceived discomfort.

Study Design and Population Focus

The design of the main clinical trials was specific and highly controlled. These trials utilized an enriched enrollment, randomized withdrawal (EERW) design. This meant that only adult patients (typically between 18 and 75) who were already taking opioids and who showed an initial, positive response to the study drug were then chosen and randomized for the final phase of the trial. The outcomes that research examined included how often a patient achieved a certain patient-reported outcomes describing perceived discomfort (a 'responder' status) and the Subject Global Assessment of Medication (SGAM) score.

What is Still Uncertain About Zohydro's Evidence

Long-term effects are not fully established and certainty remains low compared to the initial 12-week controlled data. The evidence highlights what is known — and what is still uncertain — regarding prolonged use. The use of the enriched enrollment, randomized withdrawal (EERW) design in the pivotal trials means the results apply only to the populations studied (initial responders), which limits the ability to generalize findings. Research providing head-to-head comparisons with other long-acting pain treatments remains limited in the core evidence package.

Key Studies & References

1. A Randomized Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Tolerability and Safety of Hydrocodone Bitartrate Controlled-Release Capsules in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain (Trial ZX002-0801)

Common questions about Zohydro (FAQ)

Q: Does Zohydro have an abuse-deterrent formulation?

Yes, Zohydro is described in regulatory documents as having an abuse-deterrent formulation that uses BeadTek technology. This formulation is intended to reduce the risk of abuse via injection or snorting by making the capsule contents difficult to crush or dissolve. However, official information clarifies that despite this formulation, the medication retains a significant potential for addiction, abuse, and misuse.

Q: Can I take Zohydro if I am also taking an antidepressant?

Regulatory documents state that taking Zohydro with certain serotonergic drugs, which includes many antidepressants, may lead to a serious condition called Serotonin Syndrome. Because of this potential interaction, official documents emphasize the requirement for close patient monitoring when these medicines are taken together.

Q: Are there any herbal supplements that should be avoided while using Zohydro?

Official information advises patients to tell their healthcare provider about all over-the-counter medicines, vitamins, or herbal supplements they are currently using. Taking Zohydro with certain supplements could potentially cause serious side effects, and your doctor needs this complete information to assess potential risks.

Q: Can older adults use Zohydro safely?

Official product information notes that older adults are at an increased risk for life-threatening respiratory depression (severe breathing problems). Due to this heightened risk, patients in this population are advised to be carefully monitored by a healthcare provider. The medication’s processing by the body is generally comparable in older adults, but the need for close monitoring remains due to increased risk.

Q: Is Zohydro used to treat pain in children?

Regulatory documents explicitly state that the safety and effectiveness in pediatric patients have not been established. The use of the medication in children is not covered by official labeling.

Q: Can Zohydro be used during pregnancy?

Official documents warn that prolonged use during pregnancy can result in neonatal opioid withdrawal syndrome (NOWS) in the newborn. Furthermore, the medication is not recommended while breastfeeding because it may be harmful to the baby.

Q: What happens if you miss a planned dose of Zohydro?

If a dose of Zohydro is missed, the official guidance is to take the next dose at the usual scheduled time. The official guidance advises against taking more than the prescribed amount within a 12-hour period.

Q: Can Zohydro affect a person's ability to drive or operate machinery?

Official patient guidance recommends avoiding driving or activities requiring mental alertness until the patient knows how the medication affects them. This is because Zohydro can cause side effects like sleepiness (somnolence) and dizziness.

Q: What are the signs of opioid withdrawal that can occur with Zohydro?

Opioid withdrawal is a known effect if the medication is stopped abruptly. According to official data, symptoms may include restlessness, anxiety, insomnia, sweating, muscle aches, nausea, vomiting, and diarrhea. Abrupt discontinuation is strongly discouraged, as gradual tapering is the official protocol to help prevent these effects.

Q: Are there any foods or drinks that should be avoided with Zohydro?

Regulatory documents specify that alcohol and products containing alcohol should not be consumed, as co-ingestion can result in a rapid and potentially fatal increase in plasma hydrocodone levels. The drug itself may be taken with or without food.

Q: What is known about the long-term use of Zohydro?

Official information indicates that long-term exposure is associated with the expected development of physical dependence and tolerance. Research studies providing certainty on the medication’s effects beyond the initial 12-week controlled trials are not fully established.

Q: Has Zohydro been studied in people with kidney problems?

Yes, official labeling addresses the use of Zohydro in patients with renal impairment (kidney problems). These patients should begin therapy with a low dose and be monitored closely. The dose adjustment is specified due to the potential for slower removal of the medicine from the body in this population.

Q: Why do official documents mention 'risk evaluation and mitigation strategies' for Zohydro?

The FDA requires a Risk Evaluation and Mitigation Strategy (REMS) for opioid analgesics like Zohydro. This strategy is mentioned in official documents to help ensure that the benefits of the drug outweigh the known risks of addiction, abuse, and misuse in the patient population.

Q: Can taking Zohydro affect hormone levels?

Official documents note that opioids can cause a serious condition called adrenal insufficiency, which involves decreased production of cortisol, a hormone. This condition may present with symptoms like nausea, vomiting, and lack of energy, and requires medical attention.

Q: What if I have allergies to other pain medications; can I still take Zohydro?

Official information clarifies that the medication is contraindicated (should not be used) if a patient has a known allergy or hypersensitivity to hydrocodone or any component of the capsule. Official guidance emphasizes the importance of informing the doctor of any known drug allergies.

Q: What is the recommended period of time a patient should use Zohydro?

Zohydro ER is indicated for pain requiring daily, around-the-clock, long-term opioid treatment. The specific duration of time an individual patient should use the medication is not defined by a standard time frame and must be determined by a healthcare provider based on their continuous need for pain management.

Q: Is Zohydro safe for people with liver disease?

Patients with severe hepatic impairment (liver disease) must initiate dosing with the lowest available strength. These patients require close monitoring for adverse effects due to the body's reduced ability to clear the medicine.

Q: Does Zohydro have different strengths available?

According to official product information, Zohydro ER is supplied in multiple extended-release capsule strengths. These strengths range from 10 mg up to 50 mg.

Q: What are the signs that Zohydro may be interacting with another medication?

Official warnings describe the signs of a potential serious interaction, particularly when taken with central nervous system depressants or serotonergic drugs. These signs could include extreme drowsiness, severe sedation, trouble breathing, or mental changes such as confusion.

Q: Can Zohydro cause changes in mood or confusion?

While common side effects include somnolence (sleepiness) and dizziness, official warnings indicate that serious side effects can involve mental changes such as confusion. For example, confusion can be a potential sign of a serious interaction like Serotonin Syndrome.

Official Storage and Disposal Requirements

Zohydro ER (hydrocodone bitartrate) must be stored and disposed of according to strict governmental regulations for controlled substances, prioritizing stability and the prevention of accidental ingestion.

Storage and Handling

Condition	Requirement
Temperature	Store at Controlled Room Temperature, 25 C (77 F), with permitted excursions between 15 C and 30 C.
Protection	Store away from heat, moisture, and light. Dispense and store in a tight, light-resistant container.
Child Safety	Store securely and strictly out of the sight and reach of children and others due to the risk of fatal accidental overdose.
Integrity	Do not cut, break, chew, crush, or dissolve the capsules; the capsule must be swallowed whole to prevent rapid drug release.

Disposal

To prevent diversion and accidental ingestion, official guidelines recommend immediate disposal. If a drug take-back program or collection site is not readily available, unused or expired Zohydro ER capsules should be promptly flushed down the toilet. This method is approved for certain dangerous opioid products where the risk of harm outweighs potential environmental concerns.